KopiYouTiao personal page - To The Moon

KopiYouTiao

No personal profile

14Follow

0Followers

0Topic

0Badge

2021-06-16

$BNGO !!

2021-06-16

sups

China's Full Truck Alliance targets over US$20 billion valuation in US IPO

2021-06-16

nice

How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?

2021-06-15

$OCGN FLYYY

2021-03-25

$Adamis Pharmaceuticals(ADMP)$ mental health worsening :(

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3572913184812852","uuid":"3572913184812852","gmtCreate":1609819524259,"gmtModify":1609819524259,"name":"KopiYouTiao","pinyin":"kopiyoutiao","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":14,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.14","exceedPercentage":"80.35%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.04","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":8,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":169660448,"gmtCreate":1623833203084,"gmtModify":1703820830592,"author":{"id":"3572913184812852","authorId":"3572913184812852","name":"KopiYouTiao","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572913184812852","idStr":"3572913184812852"},"themes":[],"htmlText":"$BNGO !!&nbsp;","listText":"$BNGO !!&nbsp;","text":"$BNGO !!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169660448","isVote":1,"tweetType":1,"viewCount":204,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169687946,"gmtCreate":1623833117185,"gmtModify":1703820826333,"author":{"id":"3572913184812852","authorId":"3572913184812852","name":"KopiYouTiao","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572913184812852","idStr":"3572913184812852"},"themes":[],"htmlText":"sups","listText":"sups","text":"sups","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169687946","repostId":"2143271764","repostType":4,"repost":{"id":"2143271764","pubTimestamp":1623829160,"share":"https://ttm.financial/m/news/2143271764?lang=&edition=fundamental","pubTime":"2021-06-16 15:39","market":"us","language":"en","title":"China's Full Truck Alliance targets over US$20 billion valuation in US IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2143271764","media":"CNA","summary":"REUTERS -China's Full Truck Alliance Co Ltd (FTA) said on Tuesday it is aiming for a valuation of over US$20 billion in its initial public offering in the United States, marking the second major U.S. stock market listing for a Chinese company this year.\n\nFTA, which styles itself as the \"Uber for ...","content":"<p>REUTERS -China's Full Truck Alliance Co Ltd (FTA) said on Tuesday it is aiming for a valuation of over US$20 billion in its initial public offering in the United States, marking the second major U.S. stock market listing for a Chinese company this year.</p> \n<p>FTA, which styles itself as the \"Uber for trucks\", said it is offering 82.5 million American Depositary Shares (ADS) at a range between US$17 and US$19 per ADS. Each ADS represents 20 Class A ordinary shares.</p> \n<p>The top end of that range would mean the company could raise as much as US$1.57 billion from the IPO. Chinese vaping firm RLX Technology Inc raised US$1.4 billion in its U.S. IPO in January.</p> \n<p>The listing plans come despite the U.S. having introduced measures that could result in foreign companies being delisted from American stock exchanges within three years if they do not comply with the country's auditing standards.</p> \n<p>Dealmakers say Chinese firms carrying out U.S. listings believe they will be able to comply with the rules and can also complete a secondary listing in Hong Kong or Shanghai within that time frame.</p> \n<p>FTA, formed out of a merger in 2017 between two digital freight platforms Yunmanman and Huochebang, is led by Chief Executive Officer Peter Hui Zhang. Zhang was earlier the regional manager of the business-to-business unit of e-commerce behemoth Alibaba Group Holding Ltd.</p> \n<p>In November, FTA was valued at nearly US$12 billion after a US$1.7 billion investment, Reuters reported. That investment round was led by Japanese conglomerate SoftBank's Vision Fund, Sequoia Capital, Permira Capital and Fidelity.</p> \n<p>China's Tencent Holdings Ltd is also <a href=\"https://laohu8.com/S/AONE\">one</a> of the company's backers.</p> \n<p><a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a>, CICC and Goldman Sachs are among the underwriters. The company will list on the New York Stock Exchange under the symbol \"YMM\".</p>","source":"can_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Full Truck Alliance targets over US$20 billion valuation in US IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Full Truck Alliance targets over US$20 billion valuation in US IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 15:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.channelnewsasia.com/news/business/china-s-full-truck-alliance-targets-over-us-20-billion-valuation-in-us-ipo-15021758><strong>CNA</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>REUTERS -China's Full Truck Alliance Co Ltd (FTA) said on Tuesday it is aiming for a valuation of over US$20 billion in its initial public offering in the United States, marking the second major U.S. ...</p>\n\n<a href=\"https://www.channelnewsasia.com/news/business/china-s-full-truck-alliance-targets-over-us-20-billion-valuation-in-us-ipo-15021758\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"YMM":"满帮","09988":"阿里巴巴-W"},"source_url":"https://www.channelnewsasia.com/news/business/china-s-full-truck-alliance-targets-over-us-20-billion-valuation-in-us-ipo-15021758","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143271764","content_text":"REUTERS -China's Full Truck Alliance Co Ltd (FTA) said on Tuesday it is aiming for a valuation of over US$20 billion in its initial public offering in the United States, marking the second major U.S. stock market listing for a Chinese company this year.\nFTA, which styles itself as the \"Uber for trucks\", said it is offering 82.5 million American Depositary Shares (ADS) at a range between US$17 and US$19 per ADS. Each ADS represents 20 Class A ordinary shares.\nThe top end of that range would mean the company could raise as much as US$1.57 billion from the IPO. Chinese vaping firm RLX Technology Inc raised US$1.4 billion in its U.S. IPO in January.\nThe listing plans come despite the U.S. having introduced measures that could result in foreign companies being delisted from American stock exchanges within three years if they do not comply with the country's auditing standards.\nDealmakers say Chinese firms carrying out U.S. listings believe they will be able to comply with the rules and can also complete a secondary listing in Hong Kong or Shanghai within that time frame.\nFTA, formed out of a merger in 2017 between two digital freight platforms Yunmanman and Huochebang, is led by Chief Executive Officer Peter Hui Zhang. Zhang was earlier the regional manager of the business-to-business unit of e-commerce behemoth Alibaba Group Holding Ltd.\nIn November, FTA was valued at nearly US$12 billion after a US$1.7 billion investment, Reuters reported. That investment round was led by Japanese conglomerate SoftBank's Vision Fund, Sequoia Capital, Permira Capital and Fidelity.\nChina's Tencent Holdings Ltd is also one of the company's backers.\nMorgan Stanley, CICC and Goldman Sachs are among the underwriters. The company will list on the New York Stock Exchange under the symbol \"YMM\".","news_type":1},"isVote":1,"tweetType":1,"viewCount":198,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169686636,"gmtCreate":1623832943025,"gmtModify":1703820821088,"author":{"id":"3572913184812852","authorId":"3572913184812852","name":"KopiYouTiao","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572913184812852","idStr":"3572913184812852"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169686636","repostId":"2143530687","repostType":4,"repost":{"id":"2143530687","pubTimestamp":1623829500,"share":"https://ttm.financial/m/news/2143530687?lang=&edition=fundamental","pubTime":"2021-06-16 15:45","market":"us","language":"en","title":"How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?","url":"https://stock-news.laohu8.com/highlight/detail?id=2143530687","media":"Motley Fool","summary":"It's way too early to worry.","content":"<p>Nearly 170 million Americans have received the COVID-19 vaccine developed by <b>Pfizer</b> (NYSE:PFE) and <b>BioNTech</b> (NASDAQ:BNTX). More than 129 million Americans have received&nbsp;<b>Moderna</b>'s (NASDAQ:MRNA) vaccine. So far, the vaccines have appeared to be both highly effective and safe.</p> \n<p>However, the Centers for Disease Control and Prevention (CDC) is convening an \"emergency meeting\" of an advisory panel on June 18. The panel will discuss higher-than-expected reports of heart inflammation issues in young men following the second dose of the two messenger RNA (mRNA) COVID-19 vaccines. How worrisome are these heart issues reported with Pfizer's and Moderna's COVID-19 vaccines?</p> \n<h2>Behind the concerns</h2> \n<p>The CDC and the U.S. Food and Drug Administration (FDA) jointly run the Vaccine Adverse Event Reporting System (VAERS), which tracks reports of any side effects after individuals have received a COVID-19 vaccine. Most adverse events reported in VAERS aren't serious.</p> \n<p>However, the CDC noticed that higher numbers of myocarditis (inflammation of the middle layer of the heart wall) and pericarditis (inflammation of the pericardium tissue that surrounds the heart) were being reported for young men than would be expected based on the number of vaccines administered. These issues were especially notable after the second dose of the mRNA vaccines.</p> \n<p>As of May 31, 372 cases of myocarditis or pericarditis had been reported in VAERS after the second dose of the Pfizer-BioNTech vaccine. Another 201 cases of heart inflammation issues had been reported after the second dose of Moderna's vaccine. Nearly 80% of these reported cases occurred in men, with a median age of 24.</p> \n<p>The potential issues aren't limited to the United States. Earlier this month, Israel's Health Ministry announced that there was a \"probable link\" between heart inflammation issues observed primarily in young men and receiving the second dose of the Pfizer-BioNTech vaccine.</p> \n<h2>Reason to worry?</h2> \n<p>The CDC hasn't established any causal link between either of the mRNA vaccines and heart inflammation issues occurring in young men at this point. Moderna issued a public statement last week that confirmed it hasn't found any causal association between its vaccine and heart inflammation \"after carefully reviewing the safety data to date.\"</p> \n<p>The number of heart inflammation issues reported thus far, while higher than expected, is still really low overall. The CDC specifically stated that \"these reports are rare, given the number of vaccine doses administered.\"</p> \n<p>It's also important to note that most individuals affected by heart inflammation issues were treated successfully. Indeed, the CDC said, \"Most patients who received care responded well to medicine and rest and quickly felt better.\"</p> \n<p>Based on what is known now, there's no reason for individuals receiving the Pfizer-BioNTech or Moderna COVID-19 vaccines to worry. Finding rare side effects with a vaccine or a drug is launched occurs frequently. Usually, the actions taken include revising guidelines for evaluating the benefit-risk balance for affected groups and the follow-up monitoring for these groups.</p> \n<p>That could be what the CDC advisory panel that's scheduled to meet later this week will do after examining the available data. It's also possible that the panel will need more data before it makes any recommendations.</p> \n<h2>Minimal movement</h2> \n<p>Should investors worry about what all of this might mean for Pfizer, BioNTech, and/or Moderna? No. Most investors haven't been worried, as evidenced by the minimal movement of the drug stocks after the initial CDC advisory committee meeting last week where the heart inflammation issues were discussed.</p> \n<p>Granted, it's possible that a clear link between the mRNA vaccines and heart inflammation issues in young men could be established. Even if that happens, though, the issues are rare enough that the number of doses administered of these vaccines probably wouldn't be impacted very much.</p> \n<p>The emergence of new coronavirus strains makes it far more likely that more mRNA vaccine doses will be needed in the future. In the big scheme of things, Pfizer's and Moderna's COVID-19 vaccines are providing a lot more reasons for celebration than for concern.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 15:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nearly 170 million Americans have received the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). More than 129 million Americans have received Moderna's (NASDAQ:MRNA) vaccine...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143530687","content_text":"Nearly 170 million Americans have received the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). More than 129 million Americans have received Moderna's (NASDAQ:MRNA) vaccine. So far, the vaccines have appeared to be both highly effective and safe.\nHowever, the Centers for Disease Control and Prevention (CDC) is convening an \"emergency meeting\" of an advisory panel on June 18. The panel will discuss higher-than-expected reports of heart inflammation issues in young men following the second dose of the two messenger RNA (mRNA) COVID-19 vaccines. How worrisome are these heart issues reported with Pfizer's and Moderna's COVID-19 vaccines?\nBehind the concerns\nThe CDC and the U.S. Food and Drug Administration (FDA) jointly run the Vaccine Adverse Event Reporting System (VAERS), which tracks reports of any side effects after individuals have received a COVID-19 vaccine. Most adverse events reported in VAERS aren't serious.\nHowever, the CDC noticed that higher numbers of myocarditis (inflammation of the middle layer of the heart wall) and pericarditis (inflammation of the pericardium tissue that surrounds the heart) were being reported for young men than would be expected based on the number of vaccines administered. These issues were especially notable after the second dose of the mRNA vaccines.\nAs of May 31, 372 cases of myocarditis or pericarditis had been reported in VAERS after the second dose of the Pfizer-BioNTech vaccine. Another 201 cases of heart inflammation issues had been reported after the second dose of Moderna's vaccine. Nearly 80% of these reported cases occurred in men, with a median age of 24.\nThe potential issues aren't limited to the United States. Earlier this month, Israel's Health Ministry announced that there was a \"probable link\" between heart inflammation issues observed primarily in young men and receiving the second dose of the Pfizer-BioNTech vaccine.\nReason to worry?\nThe CDC hasn't established any causal link between either of the mRNA vaccines and heart inflammation issues occurring in young men at this point. Moderna issued a public statement last week that confirmed it hasn't found any causal association between its vaccine and heart inflammation \"after carefully reviewing the safety data to date.\"\nThe number of heart inflammation issues reported thus far, while higher than expected, is still really low overall. The CDC specifically stated that \"these reports are rare, given the number of vaccine doses administered.\"\nIt's also important to note that most individuals affected by heart inflammation issues were treated successfully. Indeed, the CDC said, \"Most patients who received care responded well to medicine and rest and quickly felt better.\"\nBased on what is known now, there's no reason for individuals receiving the Pfizer-BioNTech or Moderna COVID-19 vaccines to worry. Finding rare side effects with a vaccine or a drug is launched occurs frequently. Usually, the actions taken include revising guidelines for evaluating the benefit-risk balance for affected groups and the follow-up monitoring for these groups.\nThat could be what the CDC advisory panel that's scheduled to meet later this week will do after examining the available data. It's also possible that the panel will need more data before it makes any recommendations.\nMinimal movement\nShould investors worry about what all of this might mean for Pfizer, BioNTech, and/or Moderna? No. Most investors haven't been worried, as evidenced by the minimal movement of the drug stocks after the initial CDC advisory committee meeting last week where the heart inflammation issues were discussed.\nGranted, it's possible that a clear link between the mRNA vaccines and heart inflammation issues in young men could be established. Even if that happens, though, the issues are rare enough that the number of doses administered of these vaccines probably wouldn't be impacted very much.\nThe emergence of new coronavirus strains makes it far more likely that more mRNA vaccine doses will be needed in the future. In the big scheme of things, Pfizer's and Moderna's COVID-19 vaccines are providing a lot more reasons for celebration than for concern.","news_type":1},"isVote":1,"tweetType":1,"viewCount":95,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187511415,"gmtCreate":1623758573937,"gmtModify":1703818324822,"author":{"id":"3572913184812852","authorId":"3572913184812852","name":"KopiYouTiao","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572913184812852","idStr":"3572913184812852"},"themes":[],"htmlText":"$OCGN FLYYY","listText":"$OCGN FLYYY","text":"$OCGN FLYYY","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187511415","isVote":1,"tweetType":1,"viewCount":154,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":358613173,"gmtCreate":1616684261992,"gmtModify":1704797457809,"author":{"id":"3572913184812852","authorId":"3572913184812852","name":"KopiYouTiao","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572913184812852","idStr":"3572913184812852"},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/ADMP\">$Adamis Pharmaceuticals(ADMP)$</a> mental health worsening :(","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/ADMP\">$Adamis Pharmaceuticals(ADMP)$</a> mental health worsening :(","text":"$Adamis Pharmaceuticals(ADMP)$ mental health worsening :(","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/358613173","isVote":1,"tweetType":1,"viewCount":351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":358613173,"gmtCreate":1616684261992,"gmtModify":1704797457809,"author":{"id":"3572913184812852","authorId":"3572913184812852","name":"KopiYouTiao","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572913184812852","authorIdStr":"3572913184812852"},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/ADMP\">$Adamis Pharmaceuticals(ADMP)$</a> mental health worsening :(","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/ADMP\">$Adamis Pharmaceuticals(ADMP)$</a> mental health worsening :(","text":"$Adamis Pharmaceuticals(ADMP)$ mental health worsening :(","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/358613173","isVote":1,"tweetType":1,"viewCount":351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169687946,"gmtCreate":1623833117185,"gmtModify":1703820826333,"author":{"id":"3572913184812852","authorId":"3572913184812852","name":"KopiYouTiao","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572913184812852","authorIdStr":"3572913184812852"},"themes":[],"htmlText":"sups","listText":"sups","text":"sups","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169687946","repostId":"2143271764","repostType":4,"isVote":1,"tweetType":1,"viewCount":198,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169660448,"gmtCreate":1623833203084,"gmtModify":1703820830592,"author":{"id":"3572913184812852","authorId":"3572913184812852","name":"KopiYouTiao","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572913184812852","authorIdStr":"3572913184812852"},"themes":[],"htmlText":"$BNGO !!&nbsp;","listText":"$BNGO !!&nbsp;","text":"$BNGO !!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169660448","isVote":1,"tweetType":1,"viewCount":204,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169686636,"gmtCreate":1623832943025,"gmtModify":1703820821088,"author":{"id":"3572913184812852","authorId":"3572913184812852","name":"KopiYouTiao","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572913184812852","authorIdStr":"3572913184812852"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169686636","repostId":"2143530687","repostType":4,"repost":{"id":"2143530687","pubTimestamp":1623829500,"share":"https://ttm.financial/m/news/2143530687?lang=&edition=fundamental","pubTime":"2021-06-16 15:45","market":"us","language":"en","title":"How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?","url":"https://stock-news.laohu8.com/highlight/detail?id=2143530687","media":"Motley Fool","summary":"It's way too early to worry.","content":"<p>Nearly 170 million Americans have received the COVID-19 vaccine developed by <b>Pfizer</b> (NYSE:PFE) and <b>BioNTech</b> (NASDAQ:BNTX). More than 129 million Americans have received&nbsp;<b>Moderna</b>'s (NASDAQ:MRNA) vaccine. So far, the vaccines have appeared to be both highly effective and safe.</p> \n<p>However, the Centers for Disease Control and Prevention (CDC) is convening an \"emergency meeting\" of an advisory panel on June 18. The panel will discuss higher-than-expected reports of heart inflammation issues in young men following the second dose of the two messenger RNA (mRNA) COVID-19 vaccines. How worrisome are these heart issues reported with Pfizer's and Moderna's COVID-19 vaccines?</p> \n<h2>Behind the concerns</h2> \n<p>The CDC and the U.S. Food and Drug Administration (FDA) jointly run the Vaccine Adverse Event Reporting System (VAERS), which tracks reports of any side effects after individuals have received a COVID-19 vaccine. Most adverse events reported in VAERS aren't serious.</p> \n<p>However, the CDC noticed that higher numbers of myocarditis (inflammation of the middle layer of the heart wall) and pericarditis (inflammation of the pericardium tissue that surrounds the heart) were being reported for young men than would be expected based on the number of vaccines administered. These issues were especially notable after the second dose of the mRNA vaccines.</p> \n<p>As of May 31, 372 cases of myocarditis or pericarditis had been reported in VAERS after the second dose of the Pfizer-BioNTech vaccine. Another 201 cases of heart inflammation issues had been reported after the second dose of Moderna's vaccine. Nearly 80% of these reported cases occurred in men, with a median age of 24.</p> \n<p>The potential issues aren't limited to the United States. Earlier this month, Israel's Health Ministry announced that there was a \"probable link\" between heart inflammation issues observed primarily in young men and receiving the second dose of the Pfizer-BioNTech vaccine.</p> \n<h2>Reason to worry?</h2> \n<p>The CDC hasn't established any causal link between either of the mRNA vaccines and heart inflammation issues occurring in young men at this point. Moderna issued a public statement last week that confirmed it hasn't found any causal association between its vaccine and heart inflammation \"after carefully reviewing the safety data to date.\"</p> \n<p>The number of heart inflammation issues reported thus far, while higher than expected, is still really low overall. The CDC specifically stated that \"these reports are rare, given the number of vaccine doses administered.\"</p> \n<p>It's also important to note that most individuals affected by heart inflammation issues were treated successfully. Indeed, the CDC said, \"Most patients who received care responded well to medicine and rest and quickly felt better.\"</p> \n<p>Based on what is known now, there's no reason for individuals receiving the Pfizer-BioNTech or Moderna COVID-19 vaccines to worry. Finding rare side effects with a vaccine or a drug is launched occurs frequently. Usually, the actions taken include revising guidelines for evaluating the benefit-risk balance for affected groups and the follow-up monitoring for these groups.</p> \n<p>That could be what the CDC advisory panel that's scheduled to meet later this week will do after examining the available data. It's also possible that the panel will need more data before it makes any recommendations.</p> \n<h2>Minimal movement</h2> \n<p>Should investors worry about what all of this might mean for Pfizer, BioNTech, and/or Moderna? No. Most investors haven't been worried, as evidenced by the minimal movement of the drug stocks after the initial CDC advisory committee meeting last week where the heart inflammation issues were discussed.</p> \n<p>Granted, it's possible that a clear link between the mRNA vaccines and heart inflammation issues in young men could be established. Even if that happens, though, the issues are rare enough that the number of doses administered of these vaccines probably wouldn't be impacted very much.</p> \n<p>The emergence of new coronavirus strains makes it far more likely that more mRNA vaccine doses will be needed in the future. In the big scheme of things, Pfizer's and Moderna's COVID-19 vaccines are providing a lot more reasons for celebration than for concern.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 15:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nearly 170 million Americans have received the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). More than 129 million Americans have received Moderna's (NASDAQ:MRNA) vaccine...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143530687","content_text":"Nearly 170 million Americans have received the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). More than 129 million Americans have received Moderna's (NASDAQ:MRNA) vaccine. So far, the vaccines have appeared to be both highly effective and safe.\nHowever, the Centers for Disease Control and Prevention (CDC) is convening an \"emergency meeting\" of an advisory panel on June 18. The panel will discuss higher-than-expected reports of heart inflammation issues in young men following the second dose of the two messenger RNA (mRNA) COVID-19 vaccines. How worrisome are these heart issues reported with Pfizer's and Moderna's COVID-19 vaccines?\nBehind the concerns\nThe CDC and the U.S. Food and Drug Administration (FDA) jointly run the Vaccine Adverse Event Reporting System (VAERS), which tracks reports of any side effects after individuals have received a COVID-19 vaccine. Most adverse events reported in VAERS aren't serious.\nHowever, the CDC noticed that higher numbers of myocarditis (inflammation of the middle layer of the heart wall) and pericarditis (inflammation of the pericardium tissue that surrounds the heart) were being reported for young men than would be expected based on the number of vaccines administered. These issues were especially notable after the second dose of the mRNA vaccines.\nAs of May 31, 372 cases of myocarditis or pericarditis had been reported in VAERS after the second dose of the Pfizer-BioNTech vaccine. Another 201 cases of heart inflammation issues had been reported after the second dose of Moderna's vaccine. Nearly 80% of these reported cases occurred in men, with a median age of 24.\nThe potential issues aren't limited to the United States. Earlier this month, Israel's Health Ministry announced that there was a \"probable link\" between heart inflammation issues observed primarily in young men and receiving the second dose of the Pfizer-BioNTech vaccine.\nReason to worry?\nThe CDC hasn't established any causal link between either of the mRNA vaccines and heart inflammation issues occurring in young men at this point. Moderna issued a public statement last week that confirmed it hasn't found any causal association between its vaccine and heart inflammation \"after carefully reviewing the safety data to date.\"\nThe number of heart inflammation issues reported thus far, while higher than expected, is still really low overall. The CDC specifically stated that \"these reports are rare, given the number of vaccine doses administered.\"\nIt's also important to note that most individuals affected by heart inflammation issues were treated successfully. Indeed, the CDC said, \"Most patients who received care responded well to medicine and rest and quickly felt better.\"\nBased on what is known now, there's no reason for individuals receiving the Pfizer-BioNTech or Moderna COVID-19 vaccines to worry. Finding rare side effects with a vaccine or a drug is launched occurs frequently. Usually, the actions taken include revising guidelines for evaluating the benefit-risk balance for affected groups and the follow-up monitoring for these groups.\nThat could be what the CDC advisory panel that's scheduled to meet later this week will do after examining the available data. It's also possible that the panel will need more data before it makes any recommendations.\nMinimal movement\nShould investors worry about what all of this might mean for Pfizer, BioNTech, and/or Moderna? No. Most investors haven't been worried, as evidenced by the minimal movement of the drug stocks after the initial CDC advisory committee meeting last week where the heart inflammation issues were discussed.\nGranted, it's possible that a clear link between the mRNA vaccines and heart inflammation issues in young men could be established. Even if that happens, though, the issues are rare enough that the number of doses administered of these vaccines probably wouldn't be impacted very much.\nThe emergence of new coronavirus strains makes it far more likely that more mRNA vaccine doses will be needed in the future. In the big scheme of things, Pfizer's and Moderna's COVID-19 vaccines are providing a lot more reasons for celebration than for concern.","news_type":1},"isVote":1,"tweetType":1,"viewCount":95,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187511415,"gmtCreate":1623758573937,"gmtModify":1703818324822,"author":{"id":"3572913184812852","authorId":"3572913184812852","name":"KopiYouTiao","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572913184812852","authorIdStr":"3572913184812852"},"themes":[],"htmlText":"$OCGN FLYYY","listText":"$OCGN FLYYY","text":"$OCGN FLYYY","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187511415","isVote":1,"tweetType":1,"viewCount":154,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}